Sangui Biotech International Inc (SGBI) financial statements (2021 and earlier)

Company profile

Business Address 352 SOUTH 200 WEST
FARMINGTON, UT 84025
State of Incorp. CO
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
Q2
9/30/2019
Q1
6/30/2019
Q4
3/31/2019
Q3
12/31/2018
Q2
9/30/2018
Q1
6/30/2018
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments15212719365021
Cash and cash equivalents15212719365021
Receivables151535    
Prepaid expense17594810121
Other undisclosed current assets6 728752960
Total current assets:53417951119179102
Noncurrent Assets
Operating lease, right-of-use asset 5  
Property, plant and equipment3      
Long-term investments and receivables   366 
Long-term investments   366 
Other undisclosed noncurrent assets   (3) (6) 
Total noncurrent assets:35  6  
TOTAL ASSETS:56467951125179102
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Debt538480478    
Due to related parties353028    
Other undisclosed current liabilities128124164529523606453
Total current liabilities:702634671529523606453
Noncurrent Liabilities
Total liabilities:702634671529523606453
Stockholders' equity
Stockholders' equity attributable to parent, including:(2)5449(478)(404)(426)(351)
Common stock33,01233,01232,96732,96732,96732,88532,864
Treasury stock, value(19)(19)(19)1919 19
Additional paid in capital4,5134,5134,5134,5134,5134,5134,513
Accumulated other comprehensive income929491   93
Accumulated deficit(37,600)(37,546)(37,504)(37,393)(37,326)(37,270)(37,180)
Other undisclosed stockholders' equity attributable to parent   (586)(578)(554)(661)
Stockholders' equity attributable to noncontrolling interest(644)(642)(641)    
Total stockholders' equity:(646)(588)(592)(478)(404)(426)(351)
TOTAL LIABILITIES AND EQUITY:56467951119179102

Income statement (P&L) ($ in thousands)

12/31/2019
Q2
9/30/2019
Q1
6/30/2019
Q4
3/31/2019
Q3
12/31/2018
Q2
9/30/2018
Q1
6/30/2018
Q4
Revenues120258441112
Cost of revenue
(Cost of Goods and Services Sold)
    (0)(0)(0)
Other undisclosed gross profit   0   
Gross profit:120258441112
Operating expenses(48)(56)(134)(82)(104)(105)(42)
Other operating expense, net     (3) 
Operating loss:(37)(56)(110)(74)(60)(96)(30)
Nonoperating income (expense)(19)12     
Foreign currency transaction gain (loss), before tax(15)22     
Interest and debt expense(3)(3)(20)3342
Other undisclosed loss from continuing operations before equity method investments, income taxes  (5)    
Loss from continuing operations before equity method investments, income taxes:(59)(47)(135)(72)(58)(92)(28)
Other undisclosed loss from continuing operations before income taxes      (16)
Loss from continuing operations before income taxes:(59)(47)(135)(72)(58)(92)(44)
Income tax expense   (1)(1)  
Other undisclosed income from continuing operations  3    
Loss before gain (loss) on sale of properties:(59)(47)(132)(73)(59)(92)(44)
Other undisclosed net income (loss)3316  (4)24
Net loss:(55)(44)(117)(73)(59)(96)(20)
Other undisclosed net income (loss) attributable to parent1124(1)(1)08
Net loss attributable to parent:(54)(43)(93)(74)(60)(96)(12)
Other undisclosed net income (loss) available to common stockholders, basic  (18)84  
Net loss available to common stockholders, diluted:(54)(43)(111)(66)(56)(96)(12)

Comprehensive Income ($ in thousands)

12/31/2019
Q2
9/30/2019
Q1
6/30/2019
Q4
3/31/2019
Q3
12/31/2018
Q2
9/30/2018
Q1
6/30/2018
Q4
Net loss:(55)(44)(117)(73)(59)(96)(20)
Other comprehensive income5741     
Other undisclosed comprehensive income  344    
Comprehensive income (loss), net of tax, attributable to parent:2(3)227(73)(59)(96)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: